The role of rituximab in the treatment of canine lymphoma: an ex vivo evaluation.

@article{Impellizeri2006TheRO,
  title={The role of rituximab in the treatment of canine lymphoma: an ex vivo evaluation.},
  author={J Impellizeri and Kathy Howell and Kathleen P McKeever and Steven E Crow},
  journal={Veterinary journal},
  year={2006},
  volume={171 3},
  pages={556-8}
}
Targeting the CD20 receptor that is common to many B-cell Non-Hodgkin's Lymphoma subtypes in people, rituximab is a chimeric monoclonal antibody which has significantly improved disease-free survival rates compared with the use of cytotoxic agents alone. This study evaluated ex vivo canine B cell binding and depletion by rituximab with flow cytometric technique as possible proof of concept for treatment of canine lymphoma. Despite immunohistochemistry supporting CD20 expression, rituximab did… CONTINUE READING

From This Paper

Topics from this paper.
8 Citations
0 References
Similar Papers

Citations

Publications citing this paper.
Showing 1-8 of 8 extracted citations

Similar Papers

Loading similar papers…